Prostatype Genomics

Prostatype Genomics EBIT Growth

The Year-over-Year EBIT Growth of Prostatype Genomics (PROGEN.ST) as of Nov 5, 2026 is 4.34 %. In the previous year, Year-over-Year EBIT Growth was -4.09 % — a change of -206.06% (higher).

EBIT Growth

4.34 %

YoY

-206.06%

Last updated:

Year-over-Year EBIT Growth of Prostatype Genomics is 2025 4.34 % . Year-over-Year EBIT Growth of Prostatype Genomics was 2024 -4.09 % . It decreases by -206.06% higher compared to the previous year.

The Prostatype Genomics EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2016
59.39 SEK
Jan 1, 2017
-98.06 SEK
Jan 1, 2018
14.18 SEK
Jan 1, 2021
6.44 SEK
Jan 1, 2022
-84.52 SEK
Jan 1, 2023
-36.80 SEK
Jan 1, 2024
-4.09 SEK
Jan 1, 2025
4.34 SEK
The Prostatype Genomics EBIT Growth history
YEAREBIT GrowthYoY
4.34 %-206.06%
-4.09 %-88.88%
-36.80 %-56.46%
-84.52 %-1,412.52%
6.44 %-54.60%
14.18 %-114.46%
-98.06 %-265.10%
59.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Prostatype Genomics Stock analysis

What does Prostatype Genomics do? Prostatype Genomics AB generates revenue by manufacturing and selling the Prostatype Test System, a comprehensive prognostic package including the Prostatype RTqPCR kit, patient database, evaluation software, and P-score accessories. The company targets clinicians and patients who require decision support for prostate cancer treatment after diagnosis, leveraging gene expression analysis of cancer cells from prostate tissue. The Prostatype Test System combines a specialized kit, database, software, and algorithm-driven data analysis to assess cancer aggressiveness and guide treatment choices. The firm's primary customers are healthcare professionals and institutions involved in prostate cancer care, utilizing the Prostatype RTqPCR kit for gene expression testing. The system's components—Prostatype RTqPCR kit, patient database, evaluation software, and P-score—are sold as an integrated solution, with the evaluation software and P-score providing algorithm-based decision support. This approach ensures clinicians receive tailored treatment recommendations based on individual patient data. Prostatype Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Prostatype Genomics stock

Year-over-Year EBIT Growth of Prostatype Genomics is 4.34 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Prostatype Genomics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Prostatype Genomics

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Prostatype Genomics